Skip to main content
Livermore
Livermore
中文EN

Tempest Therapeutics, Inc.

TPST
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001544227

No open-market purchases or sales by Tempest Therapeutics, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.44M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Tempest Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Tempest Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Tempest Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Angel MatthewCEO and President231,482IndirectJun 23, 20263
Yee John D.Director–Jun 17, 20261
Richey William DrakeDirector–Jun 8, 20261
Maestas NicholasChief Financial Officer–Apr 2, 20261
Trojanowski JustinCorporate Controller22,168Apr 2, 20261
Pellizzari Christine ADirector–Jan 28, 20261
Nichol GeoffreyDirector–Jan 28, 20261
Raab MichaelDirector–Jan 28, 20261
Simantov RonitDirector–Jan 28, 20261
Brady Stephen RPresident and CEO46,376Jan 6, 20250
Whiting SamuelChief Medical Officer9,573Jan 6, 20250
Versant Ventures IV, LLC10% Owner209,941Aug 12, 20240
Versant Venture Capital IV, L.P.10% Owner209,941Aug 12, 20240
Versant Side Fund IV, L.P.10% Owner209,941Aug 12, 20240
Versant Venture Capital VI, L.P.10% Owner209,941Aug 12, 20240
Versant Ventures VI GP-GP, LLC10% Owner209,941Aug 12, 20240
Versant Ventures VI GP, L.P.10% Owner209,941Aug 12, 20240
Versant Vantage II, L.P.10% Owner209,941Aug 12, 20240
Versant Vantage II GP-GP, LLC10% Owner209,941Aug 12, 20240
Versant Vantage II GP, L.P.10% Owner209,941Aug 12, 20240
Dubensky Thomas W.President113,343Jan 5, 20230
Woiwode ThomasDirector2,118,644IndirectJun 22, 20220
Lorenzo PierreCorporate Controller–Jun 22, 20220
Xu StellaDirector–Sep 20, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 23, 2026 (view filing)Mar 2491 daysLateAngel MatthewCEO and PresidentPPurchase+231.5K$2.16+$500.0KNew position231.5K afterDuplicate filing
Jun 23, 2026 (view filing)Mar 2491 daysLateAngel MatthewCEO and PresidentPPurchase+463.0K–––231.5K afterDerivative2 lots
Mar 25, 2026 (view filing)Mar 241 dayAngel MatthewCEO and PresidentPPurchase+231.5K$2.16+$500.0KNew position231.5K after
Aug 12, 2024 (view filing)8:33 PM ETAug 8-124 daysVersant Ventures IV, LLC and 8 others10% OwnerSSale−788.0K$1.23−$967.0K−79.0%209.9K after2 lots
Jul 8, 2024 (view filing)Jul 35 daysBrady Stephen RPresident and CEOPPurchase+35.0K$2.11+$73.8K+307.7%46.4K after
Jul 3, 2024 (view filing)Jul 21 dayWhiting SamuelChief Medical OfficerPPurchase+4.67K$2.13+$9.95K+95.3%9.57K after
Jul 2, 2024 (view filing)Jun 284 daysTrojanowski JustinCorporate ControllerPPurchase+7.50K$2.16+$16.2K+51.1%22.2K after
May 3, 2022 (view filing)Apr 294 daysWoiwode ThomasDirector, 10% OwnerPPurchase+2.12M$2.36+$5.00MNew position2.12M after
Jan 11, 2022 (view filing)Jan 74 daysDubensky Thomas W.PresidentPPurchase+2.00K$4.78+$9.56K+1.8%113.3K after
Jan 10, 2022 (view filing)Jan 64 daysWhiting SamuelChief Medical OfficerPPurchase+1.70K$4.80+$8.16K+845.8%1.90K after